Search results
Ariceum starts radionuclide Phase I trial in glioblastoma
Clinical Trials Arena· 7 days agoThe radiopharmaceutical arena is becoming more crowded as the treatment modality yields increasing...
Half Of Dementia Cases Can Be Curbed By Addressing These Key Risk Factors
NDTV· 11 hours agoMillions of cases of dementia could be prevented or delayed by reducing a range of risk factors such...
Alzheimer’s: drug delivery and the blood brain barrier conundrum
Pharmaceutical Technology· 2 days agoEarlier this month, the US Food and Drug Administration (FDA) granted market approval for Eli Lilly...
Two biotechs cut staff; AbbVie weathers biosimilar threat
BioPharma Dive· 6 days agoGlycomimetics and Cue Biopharma both revealed layoffs. Elsewhere, AbbVie’s earnings impressed Wall...
AAIC 2024: the evolution of Alzheimer’s clinical trials
Pharmaceutical Technology· 3 days agoThis could improve adverse effects and help with chronic use, he added. The availability of...
FDA approves Sun Pharma’s JAK inhibitor for alopecia
Pharmaceutical Technology· 6 days agoAlopecia areata, which was highlighted as an unmet need by professionals in the space, is now another area of expansion. Eli Lilly’s Olumiant...
RetiSpec secures $10m to accelerate eye test commercialisation
Medical Device Network· 3 days agoThe latest funding brings the company’s total fundraising to $17m. The Series A financing was led by...
Cognito’s sensory stimulation device slows decline in Alzheimer’s
Clinical Trials Arena· 2 days agoEli Lilly’s blockbuster Alzheimer’s drug Kisunla (donanemab) won FDA approval earlier this month,...
Cognition Therapeutics’ stock dips 43% following trial results for Alzheimer’s candidate
Clinical Trials Arena· 2 days agoElsewhere in the Alzheimer’s market, C2N Diagnostics revealed findings at AAIC 2024 of its...
Anavex seek EMA approval despite shaky pivotal Alzheimer’s trial data
Clinical Trials Arena· 3 days agoThere was a third anti-amyloid therapy on the market, Biogen’s Aduhelm (aducanumab) however it was...